We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DAWN
2076
DELISTED
Day One Biopharmaceuticals
DAWN
| $205K | ﹤0.01% |
+9,511
| New | +$195K |
|
2077
Ambarella
AMBA
$3.6B
| $205K | ﹤0.01% |
+2,488
| New | +$166K |
|
2078
MannKind Corp
MNKD
$1.26B
| $204K | ﹤0.01% |
38,786
-791
| -2% | -$3.24K |
|
2079
Advanced Energy
AEIS
$12.6B
| $203K | ﹤0.01% |
+2,371
| New | +$199K |
|
|
LOGC
2080
DELISTED
ContextLogic
LOGC
| $203K | ﹤0.01% |
13,878
+4,090
| +42% | +$84.1K |
|
2081
Smartbird Inc
BIRD
$22.7M
| $202K | ﹤0.01% |
+4,176
| New | +$245K |
|
|
CTLP
2082
DELISTED
Cantaloupe
CTLP
| $202K | ﹤0.01% |
+46,412
| New | +$165K |
|
2083
Starwood Property Trust
STWD
$6.16B
| $195K | ﹤0.01% |
10,661
+584
| +6% | +$11.6K |
|
2084
Root
ROOT
$828M
| $195K | ﹤0.01% |
43,437
+32,076
| +282% | +$221K |
|
2085
Entravision Communication
EVC
$1.08B
| $194K | ﹤0.01% |
40,471
-106,515
| -72% | -$522K |
|
2086
Donegal Group Class A
DGICA
$693M
| $193K | ﹤0.01% |
13,573
-24,828
| -65% | -$361K |
|
|
EGIO
2087
DELISTED
Edgio, Inc. Common Stock
EGIO
| $183K | ﹤0.01% |
4,054
+3,428
| +548% | +$264K |
|
2088
Blue Owl Capital
OWL
$18.2B
| $180K | ﹤0.01% |
16,987
+831
| +5% | +$8.77K |
|
|
VRE
2089
DELISTED
Veris Residential
VRE
| $178K | ﹤0.01% |
11,232
-35,525
| -76% | -$524K |
|
2090
PROG Holdings
PRG
$1.68B
| $177K | ﹤0.01% |
+10,512
| New | +$180K |
|
|
DSEY
2091
DELISTED
Diversey Holdings, Ltd. Ordinary Shares
DSEY
| $176K | ﹤0.01% |
+41,230
| New | +$202K |
|
|
CLDT
2092
Chatham Lodging
CLDT
$580M
| $172K | ﹤0.01% |
14,040
-55,197
| -80% | -$681K |
|
2093
Hecla Mining
HL
$11.8B
| $171K | ﹤0.01% |
30,698
-17,477
| -36% | -$86.8K |
|
2094
Clarivate
CLVT
$1.21B
| $169K | ﹤0.01% |
20,248
| – | – |
|
2095
Pebblebrook Hotel Trust
PEB
$2B
| $169K | ﹤0.01% |
12,814
-9,112
| -42% | -$139K |
|
2096
Sprinklr
CXM
$1.62B
| $168K | ﹤0.01% |
+20,534
| New | +$178K |
|
|
BORR
2097
Borr Drilling
BORR
$1.28B
| $167K | ﹤0.01% |
33,654
-38,146
| -53% | -$170K |
|
2098
TechnipFMC
FTI
$29.1B
| $165K | ﹤0.01% |
13,532
+200
| +2% | +$2.24K |
|
|
VWE
2099
DELISTED
Vintage Wine Estates, Inc. Common Stock
VWE
| $164K | ﹤0.01% |
+50,311
| New | +$154K |
|
2100
Newmark Group
NMRK
$2.52B
| $164K | ﹤0.01% |
20,523
-11,776
| -36% | -$98.2K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.